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1. Introduction 
In the past decade, an increased understanding can be witnessed about the 
pathophysiology of coronary artery disease (CAD). The dynamic nature of the disease is 
defined by the atherosclerotic plaque, endothelial function and an interaction of cellular 
elements with the vessel wall. 
Nowadays, the evaluation of coronary anatomy and function is performed mainly, if not 
exclusively, during cardiac catheterization using several invasive techniques. Ultrasound 
exploration of the coronary arteries was first suggested over 15 years ago and has been the 
object of increasing interest in recent years. Early two-dimensional equipment could not 
ensure optimal definition of a structure as small as a coronary artery. Transoesophageal 
echocardiography (TEE) is a relatively new ultrasound imaging modality that makes it 
possible to obtain high-quality images of the heart and great vessels (1). 
The severity of coronary stenosis is usually assessed by coronary angiography. The 
simple anatomic evaluation of coronary arteries has often a limited value because coronary 
flow velocity reserve (CFR), the real indicator of the functional importance of the stenosis, 
only modestly correlates with its anatomic severity. 
Numerous methods have been used to assess coronary flow and flow reserve, including 
nuclear techniques (2), coronary sinus catheterization (3), cineangiography dye washout 
curves (4), intracoronary Doppler catheters and wires (5), and positron emission tomography 
(6,7). Each technique has its own considerations of logistics, risk, methodology, and 
validation and are invasive or require extensive and costly laboratory equipment. In the last 
few years, several authors have demonstrated the possibility of monitoring the coronary flow 
velocity response to vasoactive agents in the proximal left anterior descending coronary artery 
(LAD) by means of transoesophageal Doppler echocardiography (8). 
Transoesophageal echocardiography is a widely used semi-invasive method to evaluate 
the heart structures from a "new window". Heart structures can be visualized as left atrial 
appendage, regurgitations etc. from another aspects. It has been also used for imaging the 
coronary arteries and its proximal branches. TEE is an emerging method which even capable 
of measuring the coronary blood flow velocity in the proximal LAD by Doppler method. The 
coronary flow velocity reserve of the left anterior descending coronary artery may be 
determined using TEE Doppler velocimetry at rest and during dipyridamole-induced 
hyperaemia, as initially described by Iliceto et al. (1). The procedure involves the use of 
pharmacologic agents such as dipyridamole or adenosine as coronary vasodilators. 
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Transoesophageal echocardiographic monitoring of flow velocity in the LAD with 
dipyridamole stress has been validated as an accurate means of estimating LAD flow reserve. 
The efficacy of systemic infusion of dipyridamole to determine coronary flow velocity 
reserve and to predict the functional severity of coronary stenoses by TEE Doppler has been 
recently demonstrated (2). TEE Doppler echocardiography is feasible, relatively inexpensive, 
safe, and thanks to its limited invasiveness, allows serial assessment of CFR in the same 
patient and in subjects in whom an invasive procedure is not justified. Measurement of CFR, 
once used only for research, have gained wide acceptance as an additional diagnostic 
approach in the decision-making process of diagnostic cardiac catheterisation and coronary 
interventions. 
In 80-85% of patients, angina pectoris and coronary insufficiency are caused by 
haemodinamically relevant, severe stenosis of one or more coronary arteries. In about 15-20% 
of patients, however, the coronary angiogram shows no abnormalities, although the patient 
has significant complaints, abnormal changes in the rest on the course of the attack and 
exercise electrocardiogram (ECG), and a positive response to nitroglycerin. In patients with 
angina pectoris and a normal coronary angiogram a disturbance of the coronary 
microcirculation can be resulted by vascular, extravascular, rheologic and metabolic factors. 
Previous studies have revealed that the CFR depends not only on the micro- and 
macrovascular resistance, but also on myocardial resistance (as left ventricular hypertrophy), 
on endothelial or metabolic factors (hypercholesterolaemia etc), on hyperviscosity etc. 
Determinants of CFR are multiple, and the confounding effect of various factors were 
assessed. The aim of this thesis was to determine the effects of several factors on coronary 
flow velocities and velocity reserve in patients who underwent coronary angiography. Further 
aim was to examine the correlations between CFR and aortic atherosclerosis as well as 
distensibility. 
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2. Methods 
Patient population: From the beginning of the work in december 1997, more than 700 
transoesophageal coronary flow velocity reserve examination of 554 patients were performed. 
The study population for each study will be discussed later in the individual chapters. 
Transthoracic echocardiography: Transthoracic echocardiography studies were performed 
with ATL Ultramark 9 HDI or Toshiba Powervision 8000 echocardiography machine. The 
left ventricular internal dimensions were measured by 2-dimensionally directed M-mode 
echocardiography. The left ventricular mass (LVM) was calculated according to the Penn 
convention (9). Body surface area (BSA) was calculated from height and body mass 
measurements according to the formula of Du Bois and Du Bois (10). The LVM index 
(LVMI) was calculated as LVM/BSA. Left ventricular hypertrophy was defined according to 
the criteria of Devereux (11). The ejection fraction was calculated by using the method of 
Teichholz et al. (12). The left ventricle-aorta pressure gradient was measured by means of 
continuous-wave Doppler echocardiography. 
Transoesophageal echocardiography: A complete TEE examination was carried out with an 
ATL® Ultramark 9 HDI echocardiograph using a 5.5 MHz biplane transducer or with a 
Toshiba Powervision 8000 echocardiograph using a multiplane transducer in all patients. 
- During the TEE examination, the grade of aortic atheroscleroisis was evaluated using the 
following five-grade scale list: grade 0: no AA, grade 1: intimal thickening, grade 2: <5 mm 
plaque, grade 3: >5 mm plaque, grade 4: plaque with mobile parts (13). 
- The systolic and diastolic aortic diameters, and the diastolic intimo-medial thickness were 
also measured in the transversal plane behind the left atrium during the TEE examination. In 
the case of intimal thickness or aortic plaque, the „worst place" parameters were considered 
for calculations. Many indices have been derived to describe and quantify the physical 
behaviour of vessels in response to an intraluminal force. Peterson et al. defined the Elastic 
modulus (E(p)) as an index of arterial stiffness, which describes the relationship of strain to 
intraluminal pressure in an open-ended vessel (14). The original description referred to the 
change in vessel volume, but since the arterial lumen is generally circular in cross-section, the 
equation has been modified to E(p) (mm Hg) = (SBP-DBP)/strain, where SBP and DBP are 
the systolic and diastolic pressures. Strain is the fractional pulsatile diameter change that 
occurs in an artery exposed to a given change in intraluminal pressure, and is defined as strain 
= (DS-DD)/DD, where DS is the systolic diameter, while DD is the diastolic diameter. 
Young's circumferential static elastic modulus (E(s)) was evaluated via (15) E(s)=E(p)*DD/2 
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h, where ,,h" is the diastolic intimo-medial thickness. The blood pressure and heart rate were 
monitored continuously during the examination. 
Dipyridamole stress TEE examinations were carried out according to the standard protocol 
proposed by Iliceto et al. (8). In all the patients, the aortic root and the proximal portion of the 
LAD were visualized in the transversal plane. The coronary blood flow was first visualized by 
colour Doppler flow imaging. A biphasic coronary flow waveform was recorded in the LAD 
by pulsed Doppler. Flow measurements were made under baseline conditions and after the 
administration of 0.56 mg/kg dipyridamole during 4 minutes. The peak velocities were 
th 
measured in the 6 minute at maximal vasodilation. All measurements were recorded on 
super-VHS videotape. In each case, five consecutive cycles were measured and averaged. The 
CFR was calculated as the ratio of the hyperaemic to the basal peak (CFR) and those of the 
mean (mean CFR) diastolic flow velocity. 
Coronary angiography: Selective coronary angiography was performed by the Seldinger 
technique. The stenosis was evaluated qualitatively from multiple projections. Coronary 
stenosis was assessed with the Siemens HiCor™ biplane angiographic system; a lumen 
diameter reduction >70% was considered to be significant when the „worst view method" was 
applied in at least one projection. 
Statistical analysis: Data are reported as means+standard deviations; 95% confidence 
intervals are also given. Analyses were performed with a standard software package (SPSS 
9.0, SPSS Inc. Chicago, IL, USA). For group comparisons, Student t test or analysis of 
variance (ANOVA) were applied. For dichotomous values, Fisher's exact test was used. To 
establish the prediction power of the variables, receiver operating characteristic (ROC) curves 
were constructed and the areas under curves are reported, p<0.05 was considered statistically 
significant. Binary logistic regression tests were performed to study the correlation of the 
variables. 
To examine the role of parameters in the evaluation of the severity of coronary artery disease, 
variables showing significant correlations were entered in a multiple regression analysis; a 
statistical model was created in order to assess the overall predictive value. A likelihood ratio 
test was performed to evaluate the difference between the model with or without entering the 
grade of aortic atherosclerosis (section 4.2.1). 
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3.Aims 
1. To evaluate the dependence of CFR on the result of coronary angiograms. 
2. To determine the diagnostic value of transoesophageal CFR measurement for the 
identification of significant coronary stenosis in patients with severe aortic stenosis 
(AOS). 
3. To investigate the effect of aortic valve replacement on the diastolic velocities and 
CFR in patients with a negative coronary angiogram by using stress TEE during an 
average follow-up of 15 months. 
4. To examine whether it is possible to differentiate patients with AOS with or without 
significant stenosis of the LAD on the basis of the age, gender, hypertension, diabetes 
mellitus, hypercholesterolaemia, the CFR and the grade of aortic atherosclerosis (AA) 
evaluated by stress TEE in the course of the same semi-invasive examination. 
5. To examine the CFR in patients with hypertrophic cardiomyopathy (HCM) in 
comparison with normal controls, measured by stress TEE. The effects of obstruction 
on the CFR were also examined in HCM patients. 
6. To evaluate the relationship between the actual cholesterol level, the application or not 
of lipid-lowering therapy and the CFR measured by stress TEE in patients without 
major coronary artery disease. 
7. To test whether known risk factors, the CFR and the grade of AA detected by stress 
TEE in the course of the same semi-invasive examination is able to distinguish 
between patients with significant LAD stenosis or with multivessel disease. 
8. To assess the elastic properties of the descending aorta and the CFR evaluated during 
the same stress TEE examination in patients after coronary angiography. 
9. To determine the aortic distensibility indices of the descending aorta and the CFR in 
the course of the same stress TEE examination in patients with different grades of AA. 
10. To test the hypothesis that the elastic properties of the descending aorta of AOS 
patients reveal early signs of stiffness of the aorta. For this purpose, we compared the 
CFR and aortic distensibility indices in three different patient populations: control 
patients without valvular and coronary artery disease, patients with aortic stenosis with 
normal epicardial coronary arteries, and patients with significant LAD stenosis. 
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4. Results 
4.1. Factors affecting coronary flow velocity reserve 
4.1.1. The effect of micro- and macrovascular resistance on CFR - dependence on 
coronary angiography 
Study population: The study comprised 152 patients (109 men, 43 women) who underwent 
dipyridamole stress transoesophageal echocardiography and coronary angiography. The mean 
age was 56.4±11.0 years, the youngest patient was a 22 year-old man, while the oldest a 73 
year-old woman. The ratio of patients with hypertension and diabetes mellitus did not differ 
significantly between the groups, and there was no case with significant valvular heart 
disease. 
Results: 
The CFR of 152 patients depending on the coronary angiogram are presented in Table 1. A 
significant difference was observed between groups signed by star and patients with negative 
coronary angiogram (p<0.05). Diastolic coronary flow velocities of patients in different 
groups are presented in Table 2. The resting diastolic flow velocities of patients with 
significant LAD disease or with multi-vessel disease and of cases with suspected syndrome X 
were significantly increased compared to negative patients. The diastolic flow velocities 
measured at the peak of stress of patients with significant LAD, left circumflex (CX) coronary 
artery disease and multi-vessel disease and cases with suspected syndrome X were found to 
be significantly decreased (Table 2). 
CFR in patients with negative coronary angiogram: From this patient population nineteen 
patients showed a negative coronary angiogram. The average CFR was 3.19±1.15. 8 patients 
were found, who had typical anginal pain, positive treadmill test with significant ST-T 
changes, but normal epicardial coronary arteries during coronary angiography. The average 
CFR was 1.24±0.21 (mean CFR: 1.2310.36) which was significantly different compared to not 
only patients with negative coronary arteries without positive stress test but also cases with 
LAD single-vessel disease (Table 1). 
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CFR of patients with non-significant coronary artery disease: No significant difference 
was found in CFR in patients with different kinds of non-significant coronary artery disease, 
but it was significantly decreased compared to patients with negative coronary angiogram. 
There was a significant difference between patients with non-significant CAD and patients 
with significant LAD disease, patients with multivessel-disease or cases with suspected X 
syndrome. There was no difference in CFR between patients with non-significant CAD and 
cases with significant right coronary (RC) or CX single-vessel disease. 
CFR of patients with significant single-vessel coronary artery disease: Significant single-
vessel coronary artery disease was diagnosed if significant stenosis of a major coronary artery 
(left anterior descending coronary artery, left circumflex coronary artery, right coronary 
artery) or its main branch (I. diagonal, obtus marginalis) was found during the coronary 
angiography. The CFR of patients with LAD single-vessel disease was significantly decreased 
compared to cases significant CX or RC single-vessel disease (Table 3). 
CFR of patients with significant stenosis of the LAD: 34 patients showed a significant 
stenosis in the LAD during coronary angiography. None of them had undergone percutan 
transluminal coronary-angioplasty (PTCA) and/or stent-implantation, previously. The CFR of 
these patients were significantly decreased compared to patients with normal epicardial 
O 
coronary arteries (p<10 ). A non-significant difference was found in the CFR depending on 
the localisation of the stenosis of the LAD. The CFR of patients with proximal stenosis of the 
LAD was 1.84, while in cases with distal stenosises was somewhat lower (CFR: 1.75). The 
CFR of patients with significant LAD stenosis was reduced compared to cases with non-
significant stenosis, but the difference did not reached the level of significance (Table 4). 
The CFR of patients with different kinds of multivessel-disease (MVD) 
There was no difference in the CFR between patients with significant LAD and cases with 
two- or three-vessel disease. The CFR of patients with CX single-vessel disease was 
significantly increased compared to two-vessel disease (p<0.005) and to three-vessel disease 
(p<0.04). The CFR of cases with RC single-vessel disease was higher, but did not reached the 
level of significance. The CFR of patients with different kinds of multi-vessel disease are 
presented in table 5. These values are significantly decreased compared to patients with 
negative coronary angiogram, non-significant CAD and significant CX single-vessel disease. 
In patients with multi-vessel disease involving LAD the CFR is decreased. Interestingly, in 
patients with significant CX and RC disease, the CFR similarly reduced. 
8 
Table 1 CFR and mean CFR in patients with different kinds of coronary angiogram 
CFR Mean CFR Patient number 
Negative 3.19+1.15 3.1911.17 19 
Non-significant coronary artery 
disease 
2.1710.62* 2.310.65* 20 
Suspected X syndrome 1.2410.21** 1.2310.36** 8 
LAD single-vessel disease 1.7710.47* 1.7110.51* 34 
CX single-vessel disease 2.5810.87 2.5311.33 12 
RC single-vessel disease 2.1310.56* 1.9710.53* 8 
Two-vessel disease 1.9210.62* 1.710.47* 43 
Three-vessel disease 1.8310.43* 1.9610.49* 8 
*p<0.05 vs Negative 
**p<0.05 vs LAD single-vessel disease 
Table 2 Diastolic flow velocities at rest and at the peak of stress 
in different patient populations 
Resting diastolic flow velocities 
(cm/s) 
Diastoles flow velocities at the peak 
of stress (cm/s) 
Negative 49.5118.6 142.5129.3 
Non-significant coronary artery 
disease 
57.5125.0 118.9146.9 
Suspected X syndrome 66.3128.8* 93.8145.1* 
LAD single-vessel disease 65.2130.7* 108.4140.1* 
CX single-vessel disease 46.1113.6 114.6139.7* 
RC single-vessel disease 60.0113.4 123.2118 
Two-vessel disease 61.2124.5* 106.7134.1* 
Three-vessel disease 76.9132.3* 134.6145.2 
*p<0.05 vs Negative 
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Table 3 CFRs in patients with different kinds of single-vessel disease 
CFR mean CFR 
LAD single-vessel disease 1.77±0.47 1.71+0.51 
CX single-vessel disease 2.5810.87* 2.53±1.33* 
RC single-vessel disease 2.13+0.56* 1.9710.53* 
*p<0.05 vs Negative 
Table 4 CFRs of significant and non-significant LAD single-vessel patients 
LAD stenosis CFR Patient number 
>70% 1.7110.47 34 
<70% 1.9610.65 13 
p=NS 
Table 5 CFRs of patients with different kinds of multivessel disease 
CFR Mean CFR No. of cases 
LAD+CX 1.9510.68 1.7110.61 12 
LAD+RC 1.8710.49 1.6810.40 16 
CX+RC 2.0010.81 1.6010.51 11 
LM 1.7910.39 1.9810.28 4 
Three-vessel disease 1.8310.43 1.9610.49 8 
p=NS 
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4.1.2. The effect of left ventricular hypertrophy as an extravascular compressive force 
on coronary flow velocity reserve 
4.1.2.1. Coronary flow velocity reserve is patients with aortic valve stenosis 
4.1.2.1.1. How can the CFR be altered by aortic valve stenosis? 
Study population: The study population comprised 21 consecutive aortic stenosis patients 
with normal coronary arteries (group 1), 21 patients with anatomically normal coronary 
arteries without aortic stenosis (group 2) and 37 patients with significant (visually assessed 
diameter reduction >75%) left anterior descending coronary artery disease without AOS 
(group 3). None of the patients with LAD stenosis had undergone previous percutaneous 
transluminal coronary angioplasty or stent implantation. The demographic and clinical data on 
the patients are shown in Table 6. Severe aortic stenosis was diagnosed if the mean left 
ventricle-aorta poststenotic gradient was higher than 50 mm Hg. 
Transthoracic echocardiography: The mean left ventricle-aorta pressure gradient of the 
patients with aortic stenosis was 94±22 mmHg. The left ventricular mass (LVM) and LVM 
index (LVMI) was significantly higher in group 1 than in groups 2 and 3 (p<0.05). There was 
no significant difference in ejection fraction (EF) between the three groups (Table 7). 
Dipyridamole stress transoesophageal echocardiography: During the stress, no patient 
displayed either significant ST-T changes in the ECG or limiting side-effects. The heart rate 
was significantly higher, and the diastolic and the systolic blood pressures were lower in all 
groups after the dipyridamole infusion (p<0.05) (Table 8). In patients with aortic stenosis, the 
systolic blood pressure was lower than in patients with left anterior descending coronary 
artery disease or in the normal subjects following the dipyridamole infusion. The resting 
diastolic flow velocity was significantly higher in group 1 and 3 compared to group 3. The 
post-hyperaemic diastolic flow velocity was significantly lower in group 1 and 3 compared to 
group 3 (Table 9). 
Comparison of CFR in the three 3 groups: The coronary flow velocity reserve and the 
mean coronary flow velocity reserve were significantly higher in group 2 than in groups 1 and 
3 (p<0.009) (Table 9). 
Table 6 Demographic and clinical data on the patients 
Group 1 
(AOS) 
Group 2 
( N e g ) 
Group 3 
(LAD) 
Age (years) 58±10 49±10 56+9 
Men/women 11/10 10/11 24/13*§ 
Hypertension (%) 13/21(62) 8/21 (3 8)@ 24/37(65) 
Diabetes mellitus (%) 7/21(33) 2/21(10) 10/37(27) 
Cholesterol (mmol/l) 4.86±0.44 5.34+0.49 5.57±0.36* 
Smoker status (%) 2/21(5) 7/21 (33)@ 3/37 (8) 
Typical angina (%) 16/21 (76) 17/21 (63) 36/37 (97)*§ 
Atypical chest pain (%) 2/21 (5) 4/21 (19) 2/37 (5) 
Left ventricular 
hypertrophy in the resting 
ECG (%) 
20/21 (95)§@ 8/21 (38) 8/37 (22) 
Medication: - P-blockers (%) 8/21 (38)§@ 15/21 (71) 27/37 (73) 
- ACE inhibitors (%) 15/21 (71) 7/21 (33)*@ 27/37 (73) 
- Nitrates (%) 10/21 (48) 7/21 (33) 27/37 (73)*§ 
- Calcium antagonists (%) 4/21 (19) 7/21 (33) 8/37 (22) 
- Lipid-lowering 
therapy (%) 
2/21 (5) 4/21 (19) 14/37 (38)* 
- Antidiabetics (%) 1/21 (5) 2/21 (10) 4/37(11) 
Values are expressed as number (%) unless otherwise indicated. 
*p<0.05 vs group 1; §p<0.05 vs group 2; @p<0.05 vs group 3 
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Table 7 Left ventricular mass, left ventricular mass index and ejection fraction 
in the three groups 
LVM (g) LVM I (g/m2) EF (%) 
Group 1 (AOS) 380.31119* 185.6118.1* 63120 
Group 2 (Neg) 234.21100.2 127.1120.2 65111 
Group 3 (LAD) 268.2170.2 130.8121.3 62111 
*p<0.05 groupl vs groups 2 and 3 
Table 8 Heart rate (HR), systolic (SBP) and diastolic (DBP) blood pressure in the three 
groups ('max' means measured at the peak of stress) 
HR rest 
(1/min) 
HR max 
(1/min) 
SBP rest 
(mm Hg) 
SBP max 
(mm Hg) 
DBP rest 
(mm Hg) 
DBP max 
(mm Hg) 
Group 1 77.4113.3 90.6112* 137.7126.4 113.4127.2* 88127.2 73.8121.9* 
Group 2 73.5115.9 92.7119.1* 139121.3 123.2120.4* 88.2127.2 74.5117.3* 
Group 3 80.1114.1 94.1116.4* 149.5128.3 130.4122.6* 89.8118.9 74.8115.4* 
*p<0.05 dip vs rest data 
Table 9 Coronary flow velocities and CFRs in the three groups 
Group 1 Group 2 Group 3 
Drest (cm/s) 64.3124.1* 53.2119.2 64.8129.3* 
Dmax (cm/s) 123.3141.6* 147.7125.5 109.5141* 
CFR 1.9810.52* 3.1311.06 1.8210.46* 
Mean CFR 1.9110.62* 3.1911.17 1.7610.5* 
*p<0.05 group 2 vs groups 1 and 3 
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4.1.2.1.2. The effect of aortic valve replacement on CFR in patients with a normal 
coronary angiogram 
Study population: 30 patients (17 women and 13 men) were enrolled in the follow-up study; 
they had a normal coronary angiogram and aortic stenosis and underwent dipyridamole stress 
TEE between Februar 1998 and May 2000. All these patients were recalled for a control 
examination. One woman died after femur fracture during the follow-up period before AVR. 
Two patients (1 woman, 1 man) died in cardiac insufficiency before AVR. Three patients (2 
women and 1 man) were not operated on because none of them wanted to participate. Three 
patients (1 woman and 2 men) underwent AVR, but did not participate in this study. Stress 
TEE was performed 1231137 days before AVR and 4971167 days after AVR. 21 patients 
remained in this follow-up study. The demographic and clinical data are presented in Table 
10. The medication applied pre- and postoperatively are presented on Table 11. 
Transthoracic echocardiography: The average gradient of aortic stenosis was 89.5122.4 
mm Hg. After AVR, the average aortic gradient decreased to 26.219 mm Hg. The left 
ventricular dimensions, LVM and LVMI index are presented in Table 12. 
Dipyridamole PSTEE: During the stress, no patient displayed either significant ST-T 
changes on ECG or limiting side-effects. The diastolic blood pressure at rest was significantly 
higher after AVR. The heart rate was higher, while the blood pressure was lower after 
dipyridamole infusion in both pre- and post-AVR conditions (Table 13). The average baseline 
diastolic flow velocity was 62.2125.5 cm/s before AVR and 40.1113.6 cm/s after it. The 
average diastolic velocity measured at maximum stress was 117142.8 cm/s before AVR, and 
91.5134 cm/s after it (Table 14). Systolic velocities (Srest, Smax) during stress were also 
examined, and the ratio Smax/Srest was calculated before and after AVR (Table 14). 
Comparison of CFR before and after AVR: The calculated CFR was 1.9610.5 before 
AVR, and 2.3710.8 after it. 
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Table 10 Demographic and clinical data on the patients who underwent the follow-up 
Before AVR After AVR 
No. of patients 21 21 
Age (years) 68+8 6919 
Male gender (%) 9(43) 9(43) 
Hypertension (%) 16(76) 16(76) 
Diabetes mellitus (%) 5(24) 5(24) 
Cholesterol (mmol/l) 4.6610.22 4.6310.32 
Smoker status (%) 2(10) 0 (0) 
Typical angina (%) 9(43) 1(5)* 
Atypical chest pain (%) 1 (5) 0 (0) 
Body weight (kg) 74.3+11.6 75.8110.7 
Body surface area (m2) 1.8810.07 1.8810.06 
Values are expressed as number (%) unless otherwise indicated. 
*p<0.05 vs before AVR 
Table 11 The most important medication applied 
Before AVR After AVR 
ß-Blocker (%) 11(53) 18(86)* 
ACE inhibitor (%) 18(86) 18(86) 
Nitrate (%) 9(43) 7(33) 
Ca-antagonist (%) 5(24) 6(29) 
Diuretics (%) 10(48) 10(48) 
Coumarin (%) 3(14) 21 (100)* 
ASA (%) 7(33) 0(0)* 
Lipid-lowering therapy (%) 6(29) 8(38) 
Values are expressed as number (%) unless otherwise indicated. 
*p<0.05 vs before AYR 
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Table 12 Echocardiographic data before and after AYR 
Before AVR After AVR p value 
IVS(mm) 13.813.4 1111.7 0.002 
PW (mm) 12.712.3 10.811.6 0.003 
EDD (mm) 52.716.5 49.715.5 0.12 
EF (%) 64.117.3 65.317.7 0.62 
LVM (g) 354.91107.9 223.8173.6 0.001 
LVMI (g/m2) 189.6159.7 118.8137.7 0.001 
p = N S 
Table 13 Heart rate and blood pressure before and after AYR 
HR rest 
(1/min) 
HR dip 
(1/min) 
SBP rest 
(mm Hg) 
SBP dip 
(mm Hg) 
DBP rest 
(mm Hg) 
DBP dip 
(mm Hg) 
Before AVR 80.1115.4 94.2114** 136.5125 129126.1 82.2111.2 76.6120.5 
After AVR 79.5112.3 89.9117.5 154.2126.1 132122.1® 92.1110.2* 75.1118.1& 
*p<0.01 vs before AVR; **p<0.01 vs HR rest; @p<0.01 vs SBP rest; 
&p<0.01 vs DBP rest 
Table 14 Coronary flow velocities and CFR before and after AVR 
Before AVR After AVR 
S rest (em/s) 27.3114 2117.6 
S max (em/s) 43.7115 42.6117.6 
S max/S rest 1.7910.69 2.1711.03 
D rest (cm/s) 62.2125.5 40.1113.6* 
D max (em/s) 117142.8 91.5134** 
CFR 1.9610.5 2.3710.8*** 
*p<0.01 vs before AVR; **p<0.05 vs before AVR; ***p<0.05 vs before AVR 
16 
4.1.2.1.3. The comparative value of the aortic atherosclerosis and the CFR in the 
prediction of patients with aortic stenosis with coronary artery disease 
Study population: Consecutive AOS patients who underwent coronary angiography were 
examined by stress TEE in order to assess the CFR. Investigators were blinded to the result of 
coronary angiogram. From this patient population, 21 AOS patients with anatomically normal 
coronary arteries (group 1) and 18 AOS patients with significant (visually assessed diameter 
reduction >75%) LAD stenosis (group 2) were selected for the present study. 
Demographic and clinical data are presented in Table 15. The prevalences of traditional risk 
factors, typical angina and atypical chest pain were not statistically different in the two patient 
groups. Only the prevalence of grade 2 or 3 AA was significantly increased in AOS patients 
with significant LAD stenosis. Average grades of AA are presented in Figure 1. 
Transthoracic echocardiography: The mean left ventricle-aorta pressure gradient of the 
patients with AOS with negative coronary arteries was 81 ±30 mm Hg, while that of the AOS 
patients with severe LAD disease was 80+20 mm Hg. There was no significant difference in 
standard echocardiographic parameters between the two groups (Table 16). 
Dipyridamole stress transoesophageal echocardiography: During the stress, no patient 
displayed either significant ST-T changes in the ECG or limiting side-effects. The coronary 
flow velocities and CFRs did not differ in the two patient groups (Table 17). 
Differentiation of AOS patients with severe LAD disease from AOS patients with a 
negative coronary angiogram: Binary logistic regression and ROC curves were utilized to 
establish the prognostic power of the traditional risk factors, the CFR and the grade of AA for 
the selection of AOS patients with significant stenosis of the LAD from AOS patients with 
normal coronary arteries (Table 18). Only the grade of AA (ROC area,73%, p<0.02) 
displayed good value for the prediction of AOS with significant LAD stenosis. All the other 
parameters including hypertension, hypercholesterolaemia, diabetes mellitus, age, gender, and 
the CFR were without any prognostic power. Only variables with relatively small (p<0.2) 
univariate p-values were included in the multivariate model, namely, the grade of aortic 
atherosclerosis, the age, the male gender and the CFR also included as possible predictors. As 
a result, only the grade of aortic atherosclerosis remained as a significant predictor of LAD 
disease (x2=7.29, df=l, p=0.007). 
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Table 15 Demographic and clinical data on the patients 
Group 1 
(AOS) 
Group 2 
(AOS-LAD) 
No. of patients 21 18 
Age (years) 62±11 66±6 
Male gender (%) 8(38) 11 (61) 
Hypertension (%) 12(57) 13 (72) 
Diabetes mellitus (%) 2(10) 4(22) 
Hypercholesterolemia (%) 5(24) 3(17) 
Typical angina (%) 10(48) 9(50) 
Atypical chest pain (%) 1(5) 1 (6) 
Presence of grade 2 or 3 aortic 
atherosclerosis (%) 
7(33) 14 (78)* 
Values are expressed as number (%) unless otherwise indicated. 
*p<0.01 vs group 1 
Table 16. Transthoracic echocardiographic parameters 
Group 1 Group 2 
IVS (mm) 13.4+3.5 13.9+2.9 
PW (mm) 12.0±2.1 13.6+2.8 
EDD (mm) 51.9+6.8 55.2+5.9 
EF (%) 62.8+11.2 61.0+8.6 
LVM (g) 322+91 408+133 
LVMI (g/m2) 169+48 209+73 
Peak aortic gradient 
(mm Hg) 
81+30 80+20 
p=NS 
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Table 17 Coronary flow velocities, ratio Smax/Srest and CFR in patient groups 
Group 1 
(AOS) 
Group 2 
(AOS-LAD) 
Srest (cm/s) 26.2111.0 29.7117.0 
Smax (cm/s) 45.6115.5 52.6130.3 
Smax/Srest 1.9310.94 1.8810.67 
Drest (cm/s) 60.8121.9 68.7127.7 
Dmax (cm/s) 119.9136.8 117.2150.6 
CFR 2.0810.56 1.8410.34 
p=NS 
Table 18 Differentiation of AOS patients with significant LAD stenosis from AOS 
patients with normal coronary arteries 
Variable ROC area (95% CI) 
P value 
Of 
ROC 
Binary logistic 
regression 
OR P value 
(95% CI) 
Hypertension 0.44 
(0.25-0.62) 
0.52 0.58 
(0.15-2.26) 
0.43 
Diabetes 
mellitus 
0.44 
(0.25-0.63) 
0.52 0.39 
(0.06-2.44) 
0.31 
Hypercholeste-
rolaemia 
0.54 
(0.36-0.73) 
0.66 1.67 
(0.34-8.26) 
0.53 
Age 0.56 
(0.38-0.75) 
0.50 1.06 
(0.98-1.14) 
0.16 
Male gender 0.62 
(0.44-0.79) 
0.22 2.55 
(0.70-9.31) 
0.16 
CFR 0.38 
(0.20-0.56) 
0.21 0.32 
(0.07-1.41) 
0.13 
Grade of aortic 
atherosclerosis 
0.73 
(0.57-0.89) 
0.02 7.00 
(1.67-29.38) 
0.01 
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4.1.2.2. Coronary flow velocity reserve in patients with hypertrophic cardiomyopathy 
Study population: Nineteen patients (6 women and 13 men) with hypertrophic 
cardiomyopathy (group 1) and 24 patients (13 women and 11 men) with negative coronary 
angiograms as controls (group 2) were involved in our study. All patients in group 2 
underwent coronary angiography and had a negative stress test (performed because of anginal 
pain). None of the patients had significant valvular heart disease. The demographic and 
clinical data on the patients are shown in Table 19. 
Transthoracic echocardiography! During the transthoracic echocardiography 
examinations, the site of hypertrophy was found to be on the septum; the average thickness 
was 20.7±3.7 mm. In the control patients, the septal thickness was 10.8±0.18 mm. The 
difference was mathematically significant (p<0.05). There was no difference between the 
groups examined in the value of the ejection fraction or the EDD. There was a systolic 
anterior motion (SAM) phenomenon in 6 cases, while a subvalvular gradient was observed in 
6 patients in HCM patient group (average value: 38.7±16.3 mm Hg, range: 27-67 mm Hg). 
The two phenomena were present together in 4 patients. Echocardiographic parameters are 
presented in Table 21. The LVM was significantly higher in the HCM patients. In HCM 
patients with an outflow tract obstruction, the PW and LVM were significantly higher than in 
those without such an obstruction (Table 22). 
Stress transoesophageal echocardiography: Coronary flow velocities were measured 
during stress transoesophageal echocardiography (Tables 23). The resting diastolic flow 
velocity was higher in the patients with HCM, but the difference was not significant 
statistically. The diastolic velocity measured at the peak of stress was significantly lower in 
HCM. The calculated CFR was significantly lower in the patients with HCM (2.14±0.68 vs 
3.16±1.1). In 3 HCM patients, we were not able to detect systolic coronary flow velocity at 
rest, but only at peak stress. In another 3 patients, reverse systolic flow was detected, which 
remained unchanged during stress. In the HCM patients, both under resting conditions and at 
peak stress, the systolic velocity and the ratio Smax/Srest were decreased as compared with 
the controls. The difference between the above parameters were also examined in HCM 
patients with or without a subvalvular gradient (Table 24). The differences between the 
parameters were not significant, though the baseline diastolic velocity was higher and the 
maximal diastolic velocity and the CFR were lower in the presence of a subvalvular gradient. 
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Table 19 Demographic and clinical data on the patients 
Group 1 
(HCM) 
Group 2 
(controls) 
Age (years) 48±9 50+10 
Men/women 13/6 12/12 
Hypertension (%) 6/19(32) 10/24 (42) 
Diabetes mellitus (%) 0/19(0) 0/24 (0) 
Typical angina (%) 5/19(26) 18/24 (75)* 
Values are expressed as number (%) unless otherwise indicated. 
*p<0.05 vs group 1 
Table 20 Heart rate (HR), systolic (SBP) and diastolic (DBP) blood pressure 
in the groups 
HRrest 
(1/min) 
HRmax 
(1/min) 
SBPrest 
( mm Hg) 
SBPinax 
(mm Hg) 
DBPrest 
(mm Hg) 
DBPmax 
(mm Hg) 
Group 1 76.5114.2 93.6114.8* 151.3126.7 133.2123.3* 92116.3 79.9120* 
Group 2 76.9111.3 101.5119.2* 136.6120 120.4111.9* 84.5115.9 71.6114.4* 
*p<0.05 resting vs peak data in group 1 
Table 21 Important echocardiographic parameters and LVM in the groups 
Group 1 Group 2 p value 
No 19 21 -
EF (%) 71.619.8 64.6110.3 NS 
EDD (mm) 46.917.4 52.410.6 NS 
IVS(mm) 20.713.7 10.810.18 0.05 
PW (mm) 11.412.4 10.611.5 NS 
LVM (g) 410.71112.8 264.6179.4 0.0002 
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Table 22 Echocardiographic parameters in the presence or absence 
of a subvalvular gradient in HCM patients 
Subvalvular gradient Presence Absence p value 
No 6 13 -
EF (%) 76.2±7.7 69.5+10.2 NS 
EDD (mm) 50.8+11.1 45.2+4.7 NS 
1VS (mm) 21.2+4.5 20.5+3.5 NS 
PW (mm) 13.4+3.2 10.5+1.2 0.02 
LVM (g) 512.0+129.9 364.1+69.0 0.009 
Table 23 Coronary flow velocities and CFR in the groups 
Group 1 
(HCM) 
Group 2 
(controls) 
p value 
D rest (cm/s) 62.1+24.9 52.8+19.7 NS 
D max (cm/s) 124.7+40.7 147.8+26.2 0.04 
CFR 2.14+0.68 3.08+1.08 0.001 
S rest (cm/s) 8.8+29.6 23.2+7.8 0.05 
S max (cm/s) 30.6+25.7 65.9+24.1 0.001 
Smax/Srest 1.57+0.78 2.98+0.86 0.001 
Table 24 Coronary flow velocities and CFRs in patients with HCM in the presence or 
absence of obstruction 
Subvalvular gradient Presence Absence p value 
No of cases 6 13 -
D rest (cm/s) 64.2+19.5 61.1+27.8 NS 
D max (cm/s) 118.3+44.2 127.7+40.5 NS 
CFR 1.90+0.61 2.25+0.70 NS 
S rest (cm/s) 21.5+14.3 2.3+32.2 NS 
S max (cm/s) 38.0+14.7 26.5+28.5 NS 
Smax/Srest 1.71+0.54 1.51+0.89 NS 
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4.1.3. Relationship between hypercholesterolemia, lipid-lowering therapy and CFR in 
patients with a negative coronary angiogram 
Study population: 69 patients were enrolled in this study. All the patients underwent 
coronary angiography, with a negative result. None of the patients had significant valvular 
heart disease or had had a previous myocardial infarction. The patients were divided into four 
groups, depending on the cholesterol level and on the performance or not of 25±2 weeks 
lipid-lowering therapy: normocholesterolaemia (NC) without lipid-lowering therapy (LLT) 
(Group 1), normocholesterolaemia with lipid-lowering therapy (Group 2), 
hypercholesterolemia (HC) without lipid-lowering therapy (Group 3) and 
hypercholesterolaemia with lipid-lowering therapy (Group 4). The cut-off value for 
hypercholesterolaemia was 5.2 mmol/1 and that for the CFR was 2.5. The different effects of 
different forms of lipid-lowering medication were not examined. 
Demographic and clinical data on the patients are presented in Table 25. As concerns the 32 
patients who received lipid-lowering medication, the cholesterol level was normal in 16 cases 
(average cholesterol level: 4.32±0.32 mmol/1), while it remained increased in 16 patients 
(average cholesterol level: 6.38±0.51 mmol/1) at the time of the PSTEE examination. Among 
the 37 who did not receive lipid-lowering medication, normocholesterolaemia was observed 
in 30 cases (average cholesterol level: 4.22±0.41 mmol/1). The cholesterol level was increased 
in 7 patients who did not participate in lipid-lowering medication (average cholesterol level: 
6.44±0.45 mmol/1). Mean age, the ratio of male gender, the prevalence of hypertension, 
diabetes mellitus, typical angina and atypical chest pain were not different in patient groups. 
The ratio of abnormal stress test results in the previous 6 months was relatively increased in 
groups 2, 3 and 4 compared to group 1, but the difference did not reach the level of 
significance. The effect of cholesterol level on CFR was found to be significant evaluated by 
two-way ANOVA (p<0.04). 
The medication administered and the lipid-lowering therapy applied are detailed in Tables 26 
and 27. Only the use of ACE inhibitors was significantly decreased in group 3 compared to 
groups 1 and 2. 
Transthoracic echocardiography: There was no significant difference in standard 
echocardiography parameters between the groups (Table 28). 
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Dipyridamole stress transoesophageal echocardiography: During the stress, no patient 
displayed either significant ST-T changes on ECG or limiting side-effects. Systolic and 
diastolic flow velocities and CFR are presented in Table 29. In the patients who did not 
receive lipid-lowering medication and who displayed normocholesterolaemia, the CFR was 
significantly higher than in the patients who had an increased cholesterol level. 
Table 25 Demographic and clinical data on the patients 
Group 1 
(NC, no LLT) 
Group 2 
(NC, with LLT) 
Group 3 
(HC, no LLT) 
Group 4 
(HC, with LLT) 
Number of cases 30 16 7 16 
Cholesterol (mmol/1) 4.22+0.41 4.32+0.32 6.44+0.45* 6.38+0.51* 
Age (years) 55.4+11.4 56.8+7.6 52.7+2.9 54.9+8.7 
Male gender (%) 16(53) 4(25) 2(29) 7(44) 
Hypertension (%) 20 (67) 12 (75) 3(43) 12(75) 
Diabetes mellitus (%) 5(17) 6(38) 1(14) 1 (6) 
Typical angina (%) 25(83) 16(100) 6(86) 14(88) 
Atypical chest pain (%) 9(30) 4(25) 2(29) 1 (6) 
Positive stress test in the 
anamnesis (%) 
10(33) 8(50) 4(57) 8(50) 
Values are expressed as number (%) unless otherwise indicated. 
*p<0.05 vs groups 1 and 2 
Table 26 Lipid-lowering medication 
No. in Group 2 No. in Group 4 
Fluvastatin 0 1 
Simvastatin 12 12 
Fenofibrate 1 0 
Ciprofibrate 1 0 
Combined therapy 
(fibrate+statin) 
2 3 
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Table 27 Medication applied 
Group 1 
(NC, no LLT) 
Group 2 
(NC, with LLT) 
Group 3 
(HC, no LLT) 
Group 4 
(HC, with LLT) 
Number of cases 30 16 7 16 
ACE inhibitor (%) 20 (67) 11 (69) 1 (14)* 9(56) 
ß-Blocker (%) 23 (77) 10(63) 6(86) 13 (81) 
Ca-antagonist (%) 13 (43) 11 (69) 4(57) 10(63) 
Nitrate (%) 11 (37) 7(44) 4(57) 7(44) 
Diuretics (%) 7(23) 3(19) 0(0) 3(19) 
Values are expressed as number (%) unless otherwise indicated. 
* p<0.01 vs groups 1 and 2 
Table 28 Transthoracic echocardiographic data 
Group 1 Group 2 Group 3 Group 4 
EDD (mm) 52.9±7.4 50.2+6.2 52.0+4.4 54.4+10.1 
IVS (mm) 10.8+1.5 11.2+1.9 10.7+1.5 11.2+2.8 
PW (mm) 10.4+1.4 10.4+1.5 11.3+0.6 10.4+2.6 
EF (%) 64.9+12.1 64.9+10.6 61.3+2.1 66.2+14.1 
p=NS 
Table 29 Systolic and diastolic flow velocities and CFRs in the groups 
Group 1 Group 2 Group 3 Group 4 
Number of cases 30 16 7 16 
D rest (cm/s) 44.3±18.8 44.9112.6 54.6123 53.9123 
D max (cm/s) 112.2+41 108.9130.1 102.9143.2 109.1143.2 
CFR 2.6510.79 2.4710.88 2.0310.88* 2.1810.67* 
S rest (cm/s) 20.619.5 24.618 24.9110.5 24.3110.5 
S max (cm/s) 49.7120.4 54.5120 41.7120.3 49.7129 
Smax/Srest 2.5310.87 2.2111.01 1.8011.03 2.1010.94 
*p<0.05 vs group 1 
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4.2. Relationship between CFR, aortic atherosclerosis and distensibility 
4.2.1. Grade of aortic atherosclerosis: a valuable adjunct to CFR in the evaluation of 
coronary artery disease 
Study population: This study involved 125 consecutive patients (mean age: 56±11 years, 
range: 22-73) with stable angina pectoris without a previous myocardial infarction. AA grade 
determination and TEE-CFR measurement were undertaken as part of a prospective 
investigation aimed at establishment of the clinical utility of the TEE-CFR. All 125 patients 
underwent coronary angiography. Patients with significant right coronary artery or left 
circumflex coronary artery stenosis were excluded from this study, because CFR 
measurements were made in the LAD. Coronary stenosis was assessed by a digital caliper 
method, with the Siemens HiCor™ biplane angiographic system; a diameter reduction >70% 
was considered to be significant when the „worst view method" was applied. Fourty-seven 
patients with anatomically non-significant CAD (group 1), 34 patients with significant LAD 
disease (group 2) and 44 patients with MVD (group 3) were examined. None of the patients 
had significant valvular heart disease. 
Correlation of risk factors and the presence of AA with CAD: The mean age and the 
incidences of arterial hypertension and diabetes mellitus were not significantly different 
between patient groups (Table 30). The prevalence of male gender was significantly higher in 
the patients with MVD. The prevalence of hypercholesterolemia and the prevalence of grade 
2 or 3 A A were significantly lower in the patients without major CAD. The CFR was 
significantly decreased in the patients with significant LAD stenosis or MVD as compared 
with the patients without major CAD. 
Differentiation of patients with MVD from all other patients: Binary logistic regression 
and ROC curves were utilized to establish the prognostic power of traditional risk factors, 
aortic grade and the CFR for the to selection of patients with MVD (Table 31). The age (ROC 
area, 63%, P < 0.01), the gender (ROC area, 63%, P < 0.02) and the grade of AA (ROC area, 
64%, P < 0.01) displayed good value for the prediction of MVD. Hypertension, 
hypercholesterolaemia, diabetes mellitus and CFR failed to distinguish the patients with 
MVD. By binary logistic regression analysis, the age, the gender and the grade of AA were 
found to correlate significantly with the prevalence of MVD (Table 31). These variables were 
entered into multiple logistic regression analysis. In order to differentiate patients with MVD 
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from all others, the age and gender were entered as the first covariates: the model gave X = 
15.214 (df=2, p= 0.0005). When the grade of AA was entered, the power of the model 
increased significantly: Xz= 21.888, df=4, p= 0.0001; 
assessment by the likelihood ratio test 
gave X2= 6.674, df=2, p= 0.036. 
Differentiation of patients with MVD from those with LAD disease: Only the grade of AA 
(ROC area, 63%, p < 0.05) was found to exhibit good prognostic value in predicting patients 
with MVD. All other traditional risk factors, such as hypertension, hypercholesterolemia, 
diabetes mellitus, age, gender and CFR, were without prognostic power (Table 32). 
Table 30. Comparison of risk factors and presence of coronary artery disease 
Group 1 
(non-significant CAD) 
Group 2 
(LAD disease) 
Group 3 
(MVD) 
No. of cases 47 34 44 
Mean age (yr) 53.7111 56.1111.1 5919 
Male gender (%) 28 (60) 24 (71) 40 (91)* 
Arterial hypertension (%) 23 (49) 21 (62) 29 (66) 
Diabetes mellitus (%) 11 (23) 6(18) 9(20) 
Hypercholesterolemia (%) 15 (32) 18 (53)* 23 (52)* 
Presence of grade 2 or 3 aortic 
atherosclerosis (%) 
6(13) 30 (88)* 40 (91)* 
CFR 2.4111 1.7810.48* 1.8710.58* 
Values are expressed as number (%) unless otherwise indicated. 
*p<0.05 vs group 1 
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Table 31. Differentiation of patients with multivessel disease from all other patients 
Variable ROC area (95% 
CI) 
P-value 
of ROC 
Binary logistic regression 
OR p-value 
(95% CI) 
Hypertension 0.56 
(0.46-0.67) 
0.46 1.69 
(0.78-3.68) 
0.18 
Diabetes mellitus 0.49 
(0.39-0.61) 
0.98 0.98 
(0.40-2.44) 
0.97 
Hypercholeste-
rolaemia 
0.54 
(0.43-0.65) 
0.49 1.36 
(0.64-2.88) 
0.42 
Age 0.63 
(0.53-0.73) 
0.01 1.05 
(1.00-1.09) 
0.02 
Male gender 0.63 
(0.53-0.73) 
0.02 4.59 
(1.63-12.9) 
0.01 
Grade of aortic 
atherosclerosis 
0.64 
(0.54-0.74) 
0.01 2.11 
(1.22-3.64) 
0.01 
CFR 0.41 
(0.31-0.51) 
0.09 0.57 
(0.32-1.00) 
0.05 
ROC = receiver operator characteristic, OR = odds ratio, CI = confidence interval, 
CFR = coronary flow velocity reserve 
Table 32. Differentiation of patients with multivessel disease from those 
with single-vessel LAD disease 
Variable ROC Area (95% CI) 
P-value 
Of ROC 
Binary logistic regression 
OR p-value 
(95% CI) 
Hypertension 0.52 
(0.38-0.65) 
0.68 1.14 
(0.44-2.97) 
0.78 
Diabetes mellitus 0.50 
(0.37-0.63) 
0.98 1.01 
(0.33-3.08) 
0.98 
Hypercholeste-
ro lemia 
0.48 
(0.35-0.61) 
0.79 0.87 
(0.35-2.17) 
0.77 
Age 0.60 
(0.46-0.73) 
0.15 1.05 
(0.10-1.10) 
0.07 
Male gender 0.59 
(0.46-0.73) 
0.17 3.30 
(1.00-10.88) 
0.05 
Grade of aortic 
atherosclerosis 
0.63 
(0.50-0.76) 
0.05 2.15 
(1.02-4.52) 
0.04 
CFR 
0.54 
(0.41-0.67) 
0.53 1.01 
(0.41-2.5) 
0.99 
ROC = receiver operator characteristic, OR = odds ratio, CI = confidence interval, 
CFR = coronary flow velocity reserve 
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4.2.2. Coronary flow velocity reserve and indices describing aortic distensibility in 
patients after coronary angiography 
Study population: 112 consecutive patients (36 women and 76 men) with stable angina 
pectoris without a previous myocardial infarction were enrolled to this study. All of them 
underwent coronary angiography. None of the patients exhibited significant valvular heart 
disease. Cases with significant right coronary artery or left circumflex coronary artery stenosis 
were excluded from the study, because CFR measurements were made in the LAD. The 
following patient groups were compared: 17 consecutive patients with anatomically normal 
coronary arteries (group 1), 24 patients with non-significant CAD (group 2), 31 patients with 
significant stenosis of the LAD (group 3) and 40 patients with multivessel disease (group 4). 
Transoesophageal CFR measurement and transthoracic echocardiography examinations were 
applied on all cases. 
The demographic and clinical data on the patients are shown in Table 33. The prevalence of 
male gender was significantly higher in group 4 as compared with group 1. The average ages 
of the patients in groups 2, 3 and 4 were significantly higher than that in group 1 (p<0.03, 
p<0.006 and p<0.001, respectively). Interestingly, the prevalence of hypertension among the 
group 3 patients was similar to that in group 1. The prevalences of diabetes mellitus and 
hypercholesterolaemia were similar in the various patient groups. 
Transthoracic echocardiography: The thickness of the interventricular septum and the left 
ventricular mass were higher in groups 2 and 4 as compared to group 1, but the difference was 
found to be significant between groups 1 and 4 (p<0.03 and p<0.04, respectively). The 
thickness of the posterior wall and left ventricular mass index tended to be higher in groups 2 
and 4 compared to groups 1 and 3, but did not reach the level of significance. There was no 
significant difference between the four groups as concerns the ejection fraction and end-
diastolic diameter. (Table 34). 
Dipyridamole stress TEE: During stress, no patient displayed either significant ST-T 
changes in the ECG or limiting side-effects. The resting systolic and diastolic velocities were 
higher in groups 3 and 4 compared to groups 1 and 2, but did not reach the level of 
significance in these patient populations. The systolic velocities measured at the peak of stress 
did not differ between the groups. The diastolic velocities measured at the peak of stress were 
lower in groups 2, 3 and 4. Smax/Srest ratio was non-significantly decreased in groups 2, 3 
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and 4 compared to group 1. The CFR was significantly lower in groups 3 and 4 as compared 
with group 1 (p<0.002 and p<0.02, respectively). The mean CFR was also significantly lower 
between the same comparisons (p<0.001 and p<0.001, respectively). E(p) was significantly 
higher in groups 3 and 4 than in group 1 (p<0.01 and p<0.05, respectively). E(s) was higher in 
groups 3 and 4 compared to group 1. No significant relationship was found between group 2 
and groups 3 and 4. (Table 35). 
Table 33 Demographic and clinical data 
Group 1 
(normal 
coronaries) 
Group 2 
(non-significant 
CAD) 
Group 3 
(LAD disease) 
Group 4 
(MVD) 
No. of eases 17 24 31 40 
Male (%) 7(41) 14(58) 22 (71) 33 (83)& 
Age (years) 47.8±9.9 56.3+10.4* 57.3+9.8** 59.9+7.8*** 
Hypertension (%) 7(41) 20 (83)@ 18(58) 31 (78)# 
Diabetes inellitus (%) 4(24) 9(38) 6(19) 9(23) 
Hypercholes terolemia (%) 9(53) 8(33) 15 (48) 20 (50) 
Values are expressed as number (%) unless otherwise indicated. 
* p<0.03 vs group 1; ** p<0.006 vs group 1; *** p<0.001 vs group 1; 
& p<0.004 vs group 1; @ p<0.008 vs group 1; # p<0.01 vs group 1 
Table 34 Transthoracic echocardiography data 
Group 1 Group 2 Group 3 Group 4 
EDD (mm) 50.5+6.6 54.1+7.2 54.6+6.8 53.7+5.9 
IVS(mm) 9.5+1.2 11.0+2.4 10.2+1.7 11.5+2.4* 
PW (mm) 9.3+1.2 10.9+2.3 10.1+1.6 11.0+2.4 
EF (%) 62.0+8.5 63.2+10.5 62.4+10.6 62.2+10.2 
LVM (g) 215.9+56.7 307.6+131.7 272.0+72.9 311.2+108.9** 
LVMI (g/mJ) 115.4+31.5 162.8+68.4 142.6+39.0 162.0+56.6 
* p<0.03 vs group 1; ** p<0.04 vs group 1 
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Table 35 Coronary flow velocities, CFRs and indices of aortic 
distensibility in the various groups 
Coronarogram Group 1 
(normal 
coronaries) 
Group 2 
(non-significant 
CAD) 
Group 3 
(LAD disease) 
Group 4 
(MVD) 
Srest 26.1+8.5 24.5+9.6 30.0+13.1 32.1 + 12.3 
Smax 56.9+27.2 49.5+29.8 54.3+32.2 65.4+35.0 
Smax/Srest 2.31+1.08 2.04+1.02 1.86+0.66 2.19+1.13 
Drest 55.1+18.2 54.6+21.0 63.4+27.5 65.4+25.4 
Dmax 131.5+42.3 109.3+45.5 103.2+35.4 118.0+39.4 
CFR 2.60+1.23 2.06+0.69 1.75+0.45* 1.95+0.73** 
Mean CFR 2.73+0.95 2.25+0.65 1.76±0.51# 1.72+0.51## 
E(p) 0.45+0.23 0.70+0.39 0.93±0.54@ 0.83±0.55@@ 
E(s) 5.49+4.22 6.75+4.11 9.77+6.67 7.99+6.58 
* p<0.002 vs group 1; ** p<0.02 vs group 1; # p<0.001 vs group 1; 
## p<0.001 vs group 1; @ p<0.01 vs group 1; @@ p<0.05 vs group 1 
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4.2.3. Coronary flow velocity reserve and aortic distensibility indices in patients with 
different grades of aortic atherosclerosis 
Study population: A total of 113 consecutive patients (77 men and 36 women, aged 31 to 80 
years) underwent stress TEE assessment of the CFR. Patients were divided into three groups: 
cases without AA (group 1), cases with intimal thickening (group 2) and cases with aortic 
plaque (group 3). All patients had stable angina pectoris without a previous myocardial 
infarction. All patients underwent coronary angiography for the evaluation of chest pain with 
the following results: negative, non-significant CAD, significant LAD stenosis or significant 
multivessel disease. Patients with left circumflex coronary artery and/or right coronary artery 
stenosis were excluded from the study, because the CFR characterizes the functionality of the 
LAD and the measurements were made here. MVD was defined as significant stenosis of two 
or more major coronary arteries or significant left main coronary artery stenosis. 
Transthoracic echocardiography examination was performed in all cases, and none of the 
patients was found to exhibit significant valvular heart disease. 
The demographic and clinical data on the patients are shown in Table 37. The average age 
of the patients with higher grades of AA (groups 2 and 3) was significantly higher than that of 
the patients without frank A A (group 1). The numbers of patients in the subgroups, depending 
on the grade of AA and the result of coronary angiography, are presented in Table 38. The 
prevalence of patients with negative coronary angiograms was significantly less for the higher 
grades of A A (groups 2 and 3) as compared with the group 1 cases. 
TTE: The thickness of the interventricular septum (IVS) and the left ventricular mass (LVM) 
were significantly increased in group 3 as compared with group 1 (p<0.04, in both cases). The 
thickness of the posterior wall and the LVM index tended to be higher in groups 2 and 3 than 
in group 1, but the difference did not reach the level of significance. There was no significant 
difference between the three groups as concerns the ejection fraction or end-diastolic diameter 
(Table 39). 
Dipyridamole stress TEE: During stress, no patient displayed either significant ST-T 
changes in the ECG or any other procedure's limiting side-effects. The resting systolic 
velocities increased, while the systolic velocities measured at the peak of stress decreased in 
parallel with the aortic grade. The diastolic flow velocities behaved similarly. The value of 
Smax/Srest calculated from the changes in the systolic velocities decreased in parallel with 
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the grade of AA and a significant difference was found between groups 1 and 3. Finally, the 
CFR (calculated as Dmax/Drest) and the mean CFR also decreased with the aortic grades, and 
a significant difference was found between groups 2 and 3 as compared with group 1. 
Interestingly, there was no difference in CFR or mean CFR between groups 2 and 3. E(p) and 
E(s) likewise increased with the grade of AA. A significant difference was found when group 
3 was compared to groups 1 and 2 (Table 40). 
Table 37. Demographic and clinical data on the patients 
Group 1 
(no AA) 
Group 2 
(aortic intimal 
thickening) 
Group 3 
(aortic plaque) 
n 24 49 40 
Age (years) 47.7±8.7 56.8±9.6* 61.7±7.1*/** 
Male (%) 17(71) 38 (78) 22 (55)*** 
Hypertension (%) 13(54) 37 (76) 28 (70) 
Diabetes mellitus (%) 6(25) 10(20) 14(35) 
Hypercholesterolaemia 
(%) 
13(54) 17(35)**** 24 (60) 
Values are expressed as numbers (%) unless otherwise indicated. 
*p<0.001 vs group 1; ** p<0.03 vs group 2; ***p<0.05 vs group 2; ****p<0.05 vs group 3 
Table 38. Numbers of patients in the different subgroups 
Coronary angiogram Group 1 Group 2 Group 3 
Negative (%) 8 (33)* 5(10) 3 (8) 
Non-significant coronary 
artery disease (%) 7(29) 9(18) 8(20) 
LAD disease (%) 4(16) 16(33) 11 (28) 
Multivessel disease (%) 5(21) 19(39) 18(45) 
Values are expressed as numbers (%) unless otherwise indicated. 
*p<0.05 vs groups 2 and 3 
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Table 39 Transthoracic echocardiographic data 
Group 1 
(no AA) 
Group 2 
(aortic intimai 
thickening) 
Group 3 
(aortic plaque) 
EDD (mm) 52.3±7.2 54.3+6.9 53.5+5.7 
IVS (mm) 10.0+1.1 10.7+2.0 11.4+2.7* 
PW (mm) 9.8+1.1 10.5+1.9 11.1+2.7 
EF (%) 63.6+11.9 62.3+8.9 62.1 + 10.1 
LVM (g) 240.1+62.9 291.8+105.5 310.3+119.8* 
LVMI (g/m2) 128.2+33.9 152.3+55.3 162.4+62.3 
* p<0.04 vs group 1 
Table 40 Coronary flow velocities, CFRs and indices of aortic distensibility 
in the various groups 
Group 1 Group 2 Group 3 
S rest 26.5+12.1 27.9+8.8 31.6+14.1 
Smax 62.6+33.1 60.3+36.8 51.7+24.8 
Smax/Srest 2.46+0.95 2.18+1.10 1.76+0.73** 
Drest 53.8+25.5 64.5+24.7 61.5+22.7 
Dmax 129.0+43.3 116.7+40.2 103.8+37.7 
CFR 2.67+1.09 1.94+0.67* 1.74+0.47* 
Mean CFR 2.64+0.89 1.83+0.58* 1.76+0.46* 
E(p) 0.53+0.26 0.70+0.45 0.99±0.58@# 
E(s) 6.03+3.38 7.37+5.58 9.39+7.16 
* p<0.001 vs group . * * » p<0.02 vs group 1; @ p<0.002 vs group 1; # p<0.05 vs group 2 
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4.2.4. Decreased aortic distensibility and CFR in patients with significant aortic valve 
stenosis with normal epicardial coronary arteries 
Study population: The study population consisted of 71 hospitalized patients (42 men and 29 
women; mean age 57.3± 11.3 years) with stable angina pectoris. All patients underwent 
transthoracic echocardiography, stress TEE as CFR measurement and coronary angiography. 
The following patient populations were compared: patients without valvular heart disease or 
CAD (group 1), AOS patients with normal epicardial coronary arteries (group 2), and patients 
with significant stenosis of the LAD (group 3). During stress TEE, the indices of aortic 
distensibility were also evaluated and calculated from echocardiographic parameters and 
blood pressure data. 
The demographic and clinical data on the patients are shown in Table 41. The prevalence of 
male gender was significantly higher in group 3 as compared with group 2. The average ages 
of the patients in groups 2 and 3 were significantly higher than group 1, and significant 
difference was found also between the values of groups 2 and 3. The prevalences of 
hypertension, hypercholesterolemia and diabetes mellitus were similar in the various patient 
groups. 
Transthoracic echocardiography: The thickness of the interventricular septum, posterior 
wall, and the left ventricular mass and LVM index were higher in group 2 as compared to 
groups 1 and 3. There was no significant difference between the three groups as concerns the 
ejection fraction and end-diastolic diameter. (Table 42). 
Dipyridamole PSTEE: During the stress, no patient displayed either significant ST-T 
changes on ECG or limiting side-effects. The resting systolic velocities were similar in the 
patient groups. The systolic velocities measured at the peak of stress were higher in group 1 
than in group 2 and 3, but did not reach the level of significance. The resting diastolic 
velocities were increased in groups 2 and 3 compared to group 1. These differences did not 
reach the level of significance in this patient population. The diastolic velocities measured at 
the peak of stress was significantly decreased in group 3 compared to group 1. The 
Smax/Srest and CFR were significantly lower in groups 2 and 3 as compared with group 1. 
E(p) and E(s) were increased in groups 2 and 3. (Table 43). 
35 
Table 41. Demographic anc clinical data of the patients 
Group 1 
(Negative coronaries) 
Group 2 
(AOS) 
Group 3 
(LAD disease) 
No of patients 22 18 31 
Age (years) 48.5±8.2*/# 67.8±8.0 57.3±9.8* 
Male gender (%) 11 (50) 9(50) 22 (71)@ 
Hypertension (%) 12(55) 14 (78) 18 (58) 
Diabetes mellitus (%) 6(30) 5(28) 6(19) 
Hypercholesterolaemia (%) 10(45) 4(22) 16(51) 
Values are expressed as numbers (%) unless otherwise indicated. 
* pcO.OOl vs group 2; # p<0.01 vs group 3; @ p<0.05 vs group 2 
Table 42. Tranthoracic echocardiographic data 
Group 1 Group 2 Group 3 
IVS (mm) 9.6±1.3 14.4±3.8*/# 10.2±1.7 
PW (mm) 9.5±1.3 13.2±2.4*/# 10.Ü1.6 
EDD (mm) 49.8±7.2 55.5±7.4 54.6±6.8 
EF (%) 64.3±8.3 59.5±10.7 62.4±10.6 
LVM (g) 216.9±61.4 421.8±110.3 */# 272.1±72.9 
LVMI (g/m2) 115.7±35.1 220.9±58.3*/# 142.7±39.0 
* p<0.001 vs group 1; # p<0.01 vs group 2-
Table 43. Coronary flow velocities, CFRs and elastic properties of the aorta 
Group 1 Group 2 Group 3 
S rest 27.4±8.3 29.1±10.0 30.0±13.1 
Smax 64.0±25.6 51.7±25.7 54.3±21.2 
Smax/Srest 2.50±1.12 1.87±0.56 1.86±0.66@ 
Drest 55.3±16.9 68.7±23.7 63.4±27.5 
Dmax 138.9±36.0 120.1±43.1 103.2±35.4* 
CFR 2.72±1.09 1.89±0.39* 1.75±0.45# 
E(p) 0.48±0.25 0.90±0.62@ 0.93±0.54* 
E(s) 4.97±2.88 9.78±6.89@ 9.77±6.67* 
p<0.01 vs group 1; # p<0.0 11 vs group 1; @ p<0.C 5 vs group 1 
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5. Discussion 
5.1. Factors affecting coronary flow velocity reserve 
5.1.1. Coronary flow velocity reserve in patients undergoing coronary angiography (the 
effect of micro- and macrovascular resistance) 
Our results confirm the previous findings that CFR is severly reduced in patients with 
suspected microvascular disease. There was a good correlation in CFR of patients with 
suspected X syndrome (negative coronary angiography, positive stress test) with the result of 
Zehetgruber et al. (1.24±0.21 vs 1.21±0.23) (16). The CFR of patients with non-significant 
coronary artery disease was significantly decreased compared to cases with normal epicardial 
coronary arteries. The CFR of cases with LAD disease was 1.77±0.47 which correlated with 
results of Paraskevaidis et al, who found CFR 1.8 before PTC A. There was no further 
decrease in LAD-CFR if a significant stenosis of another major coronary artery was 
associated. The CFR of patients with CX and RC disease was higher compared to LAD 
disease, the difference reached the level, of significance in CX disease. In patients with CX 
and RC disease the CFR was similar as in patients with significant stenosis of the LAD and 
CX/RC. The CFR depends on the degree of the LAD stenosis (in case of higher degree of 
stenosis the CFR is more decreased), the difference was not significant. These results well 
correlated with results of Stoddard et al. (17). In patients with >70% LAD stenosis the CFR 
was 1.52 (in our patient population 1.71±0.47), in cases with lower degree of stenosis was 
1.93 (in our patient population 1.96±0.65). The CFR depends also on the location of the LAD 
stenosis. Hutchinson et al. found more decreased CFR in proximal LAD stenosis than distal 
one (18). 
5.1.2. Coronary flow velocity reserve in patients with left ventricular hypertrophy 
5.1.2.1. Coronary flow velocity reserve in patients with aortic valve stenosis 
Our results confirm the previous findings that transoesophageal Doppler echocardiographic 
measurement of the LAD velocities is a useful tool for evaluation of the CFR in patients with 
AOS. In accordance with earlier studies, we have demonstrated that the CFR is decreased in 
patients with AOS with normal coronary arteries and is reduced to similar extents in patients 
37 
with LAD disease (19-22), and it increases after AVR (23,24). However, there is no 
agreement as to the reason for the improvement of the CFR after a long-term follow-up of 
AVR. The resting diastolic velocity was significantly decreased after the operation. It was the 
main reason for the improvement in the CFR. Interestingly, the diastolic velocity measured at 
the peak of stress decreased after AVR. However, the diastolic velocities decreased to 
different extents. The improvement in the CFR showed a parallel tendency with the regression 
of the left ventricular hypertrophy. The CFR was similarly decreased in AOS patients with or 
without severe LAD disease, and could not be used to distinguish between these patient 
populations. Neither the age, the gender, the presence of the hypertension, the diabetes 
mellitus and the hypercholesterolaemia nor the CFR, only the grade of aortic atherosclerosis 
was suitable for the prediction of AOS patients with significant LAD stenosis from those 
without it. 
Pathophysiological explanation of CFR reduction: The CFR capacity of the coronary 
arteries depends on at least the following main components: 1. micro- and macro vascular 
resistance; 2. myocardial resistance; and 3. hyperviscosity and metabolic changes (25,26). In 
some pathologic conditions; changes in one or other of these factors may lead to an 
impairment of the CFR capacity. In patients with LAD disease, the key role of the increase in 
micro- and macrovascular resistance has been demonstrated by a number of authors (8,25,27-
30). On the other hand, in the absence of significant CAD, the CFR can be reduced by an 
increase in myocardial resistance, as revealed in patients with hypertension (31,32) or 
hypertrophic cardiomyopathy (33,34), but not in physiological left ventricular hypertrophic 
sportsmen (35). 
Comparison with previous studies: Pathological left ventricular hypertrophy is known to 
impair the coronary flow velocity reserve (21-24,31-34), but in endurance athletes it is 
supranormal. The reason for that is an enhanced endothelium-independent vasodilatation (35). 
Our results are in keeping with the data of Julius et al. who demonstrated CFR values in the 
range 1.5-2 in patients with aortic stenosis and normal coronary arteries, independently of the 
presence or absence of anginal pain (21). Coronary reserve was examined in patients with 
aortic valve disease before and after successful aortic valve replacement (23,24). CFR was 
diminished in preoperative compared with postoperative patients (1.66±0.44 vs 2.22±0.85; 
p<0.05) as well as with controls (vs 2.80±0.84; p<0.01). Eberli et al. investigated the CFR of 
patients with aortic valve disease before and after AVR by the coronary sinus thermodilution 
technique. Entirely different patient groups were examined before and after AVR. The CFR 
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was significantly different in the various patient groups (24). They found that the reduced 
coronary vasodilator capacity was mainly due to an elevated coronary flow at rest, while the 
maximal coronary blood flow achieved was identical to that in postoperative patients and 
controls. With the regression of the left ventricular hypertrophy, the flow at rest decreases and 
this leads to a distinct improvement in the CFR. Hildick-Smith et al. performed an adenosine 
transthoracic echocardiography follow-up study in patients with aortic stenosis and normal 
coronary arteries (23). The resting diastolic velocities were similar under pre- and post-AVR 
conditions. During hyperaemia, the post-AVR diastolic velocity was significantly higher than 
the pre-AVR diastolic velocity. The CFR was increased after AVR for aortic stenosis, this 
increase occurring in tandem with the regression of the left ventricular hypertrophy. 
Non-angiographic identification of AOS in patients with CAD: The TEE examination of 
thoracic atherosclerotic plaque is a powerful predictor of the absence of significant CAD in 
patients with AOS. Tribouilloy et al. found that the presence of aortic plaque revealed by TEE 
identified significant CAD with a sensitivity of 90.5%, a specificity of 72.5%, and positive 
and negative predictive values of 75.0% and 89.3%, respectively. They concluded that TEE 
can not be regarded as a substitute for coronary arteriography (36). Dipyridamole stress 
myocardial perfusion tomography is well tolerated, even by patients with severe AOS, and is 
of high diagnostic value in the assessment of CAD (37). Dobutamine stress echocardiography 
may be safely performed in patients with AOS. Side-effects are more common than in patients 
with CAD, but are usually well tolerated without any need for medical treatment (38). SPECT 
dipyridamole-thallium imaging is a useful noninvasive method to exclude the diagnosis of 
significant CAD (high specificity) in asymptomatic and symptomatic patients with isolated 
severe AOS (39). Adenosine stress echocardiography and adenosine stress myocardial 
perfusion scintigraphy, either separately or in combination, constitute excellent and safe 
noninvasive diagnostic methods for the detection of CAD in patients with severe AOS (40). 
Noninvasive pharmacological stress transthoracic echocardiographic examination with 
dipyridamole is one of the methods of choice for CAD identification in patients with AOS 
(41). 
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5.1.2.2. Coronary flow velocity reserve in patients with hypertrophic cardiomyopathy 
In the patients with HCM the CFR was decreased. The peak diastolic velocity was 
significantly lower, while the resting diastolic velocity was slightly increased in the patients 
with HCM because of the considerably increased LVM. In the presence of obstruction, the 
CFR was somewhat, but not significantly lower. 
Comparison with previous studies on patients with HCM: The decreased CFR in patients 
with HCM is well documented (42-61). The CFR can be measured during stress 
transoesophageal echocardiography (33,46-49), by means of intracoronary Doppler-wire 
(43,54,55), MRI (58), PET (53,57) or chromatography (56). The possibility also exist to 
measure the CFR with transthoracic echocardiography (52) (Table 44). The CFR was 
decreased in HCM in all cases. However, in our patients with HCM and in the control 
subjects the CFR varied in a wide range, which verified the well-known fact that the CFR is 
highly dependent on the method used and the vasodilator agent (25). Harjai et al. concluded 
that at this time coronary angiography is the only reliable test for the definitive diagnosis of 
co-existent coronary artery disease in HCM (48). 
The effect of outflow obstruction on the CFR: No relationship found between the outflow 
gradient and the systolic or diastolic velocities by Crowley et al. (59). An inverse relationship 
was observed by Memmola et al. between the CFR and the presence of an outflow gradient 
(33). Our results suggest that the CFR is slightly lower in the presence of obstruction. In these 
cases, the posterior wall was thicker and the left ventricular mass was significantly higher as 
compared with the HCM patients without an aortic outflow tract gradient. The baseline 
diastolic velocity was higher, while the peak diastolic velocity was lower in cases involving 
obstruction. 
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Table 44 CFR in patients with HCM in earlier studies 
Authors N CFR (HCM) CFR 
(Control) 
P Method Vasodilator agent 
Nemes et al. 
(present work) 
6 H 0 C M 
13 HCM 
1.9±0.61 
2.25±0.7 
3.16+1.1 0.001 TEE Dipyridamole 
(0.56 mg/kg) 
Dimitrow et al. (49) 
10 HCM 2.37+0.67 " " TEE Dipyridamole 
(0.56 mg/kg) 
Memmola et al. (33) 10 HCM 1.8+0.3 3.1+0.5 0.01 TEE Dipyridamole 
Asami et al. (32) 7 HCM 1.6+0.4 2.7+0.4 0.001 TTE 0.15 mg/kg /min 
adenosine 
triphosphate 
Schwartzkopff et al. (36) 13 HCM 2.28+0.6 5.34+1.49 0.003 Inert 
chromatographic 
argon method 
Dipyridamole 
(0.5 mg/kg) 
Kyriakidis et al. (S3) 20 HOCM 2.2+0.4 - - Intracoronary 
Doppler catheter 
12 mg Papaverine 
Negishi et al. (43) 8 HCM 1.7+0.1 2.6+0.1 0.05 Intracoronary 
Doppler catheter 
Vasodilator 
Krams et al. (34) 10 HCM 1.8+0.9 2.6+0.8 0.05 Intracoronary 
Doppler catheter 
Adenosine 
Lorenzoni et al. (33) 84 HCM NYHA 1=1.93+0.64 
NYH A 11=1.69+0.54 
NYHA 111=1.4+0.43 
N13-ammonia or 
015-water PET 
Dipyridamole 
Choudhury et al. (37) 15 HCM 1.45+0.52 - - 015-water PET Dipyridamole 
Kawada et al. (38) 29 HCM 1.72+0.49 3.01+0.75 0.01 VECMR Dipyridamole 
(0.56 mg/kg) 
5.1.3. Coronary flow velocity reserve and hypercholesterolemia 
CFR evaluated by dipyridamole stress TEE is decreased in patients with a negative coronary 
angiogram but increased cholesterol level compared to cases with a normal cholesterol level 
without a history of hypercholesterolaemia and who did not receive lipid-lowering therapy. In 
patients participating in inadequate lipid-lowering medication the CFR is decreased to a 
similar extent as in patients not receiving lipid-lowering therapy. In patients who receive 
lipid-lowering therapy and who exhibit an increased cholesterol level, the CFR is decreased. 
In patients with a normal cholesterol level in consequence of the lipid-lowering therapy, the 
CFR is practically normal, but is somewhat lower than in those who have never received anti-
lipid medication. 
Comparison with previous studies: The CFR evaluated by means of PET is decreased even 
in anatomically normal coronary arteries in hypercholesterolaemic patients (62). Yokoyama et 
al. reported that the CFR is reduced in patients with familial hypercholesterolaemia (FH) (63). 
Pitkanen et al. found a reduced CFR in young men with FH. The results demonstrate a very 
early coronary vasomotion impairment in hypercholesterolaemic patients (64), and also 
abnormalities in coronary flow regulation in young asymptomatic familial combined 
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hyperlipidemia patients expressing phenotype IIB (65). The results of Bailer et al. suggest that 
cholesterol-lowering therapy with simvastatin may improve the overall coronary vasodilator 
capacity assessed noninvasively by PET in patients with mild to moderate 
hypercholesterolemia. Consequently, intensive lipid-lowering therapy is recommended as a 
vasoprotective treatment for selected patients in very early stages of coronary atherosclerosis 
with the aim of preventing further disease progression (66). Mellwig et al. found that a 30% 
improvement in coronary vasodilatation capacity could be demonstrated quantitatively and 
noninvasively by PET within 24 h after a single LDL apheresis (67). The low-density 
lipoprotein cholesterol level but not the total cholesterol level, correlated inversely with the 
CFR in hypercholesterolaemic subjects (68). The improvements in stress blood flow and CFR 
are delayed as compared with the lipid-lowering effect of fluvastatin, suggesting a slow 
recovery of the vasodilatory response to adenosine (69). All of these results were examined by 
means of PET. 
5.2. Coronary flow velocity reserve and aortic atherosclerosis and distensibility 
5.2.1. Coronary flow velocity reserve and the grade of aortic atherosclerosis in the 
prediction of severe coronary artery disease 
Our results confirm that the age, the gender and the grade of aortic atherosclerosis were 
suitable for the prediction of patients with multivessel disease from all other cases. Moreover, 
a new prediction model was created which verified that the grade of AA exhibits an important 
additional value for predicting MVD. Additionally, the grade of A A exhibits good prognostic 
power for the differentiation of LAD disease patients from those with MVD. The CFR was 
significantly decreased in patients with vs. without CAD, but it was unable to distinguish 
patients with significant stenosis of the LAD from those with MVD, and had no predictive 
value in the evaluation of MVD. 
Previous studies found, that the detection of AA by TEE may be a marker for CAD in 
different patient populations (13,70-77). Acarturk et al. reported that the sensitivity and 
specificity of AA in the detection of CAD were 75.9% and 67.7% (70). The presence of 
atherosclerotic lesions in the thoracic aorta is a strong predictor of CAD only in patients <70 
years old (72,73). In elderly patients, the detection of atherosclerotic aortic plaque by TEE is 
not useful in predicting significant CAD. The detection of atherosclerotic plaque by TEE in 
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the thoracic aorta is useful in the noninvasive prediction of the presence and severity of CAD 
in patients with valvular heart disease (74), even in the elderly (75). Multiplane TEE 
examination of thoracic atherosclerotic plaque is a marker for CAD in women and is an 
especially powerful predictor of the absence of significant CAD (76). Multivariate logistic 
regression analysis showed that aortic plaques were a stronger predictor of CAD than were 
conventional risk factors (77). Khoury et al. observed a strong correlation between the 
presence of significant CAD and aortic, femoral and carotid atherosclerosis (78). The 
sensitivity and specificity of the presence of A A for the detection of CAD were the highest 
from among all the sites measured. The AA "score" (the sum of the plaque thickness in 
millimetres at distinct locations in the descending aorta) was significantly higher in patients 
with CAD than without it, though this variable did not distinguish patients with one-, two- or 
three-vessel disease. In contrast, we used a five-scale system (13) to characterize AA during 
TEE in our study, which differentiated the groups of patients with single-vessel LAD disease 
vs. MVD. The presence of significant obstruction in other vessels than the LAD impair the 
estimation of LAD stenosis and is also influenced by a microvascular dysfunction (79). The 
invasive assessment of the relative CFR overcomes this problem, but necessitates placement 
of a Doppler wire in two coronary arteries (80). However, the TEE-CFR is similarly 
decreased in patients with significant LAD stenosis and in cases with MVD, but it is unable to 
differentiate them. 
5.2.2. Coronary flow velocity reserve and indices of aortic distensibility in patients after 
coronary angiography 
Vascular properties of the aorta and CFR evaluated by stress TEE have been assessed 
simultaneously in patients after coronary angiography. The results demonstrate decreased 
CFR (and mean CFR) and increased indices of aortic distensibility in patients with LAD 
disease as compared to patients with normal epicardial coronary arteries. There were no 
further changes in these values in cases with MVD. In patients with non-significant coronary 
artery stenosis, the CFRs and stiffness moduli fall between those for the negative cases and 
patients with LAD disease/MVD. 
Comparison with previous studies: Bogren et al. used magnetic resonance imaging and 
suggested that there was a reduction in coronary flow in patients with a decreased aortic 
distensibility (81). The effect of a decreased aortic distensibility on myocardial perfusion has 
been investigated; an additive effect on myocardial ischaemia was revealed in the presence of 
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coronary artery stenosis (82,83). Previously mainly the relationship between hypertension, 
antihypertensive therapy and vascular properties was investigated, but the E(p) and E(s) in 
patients with different kinds of coronary angiogram were never have been assessed (84-89). 
The effect of hypertension on the CFR is also well-known. The 41-83% of the patients in the 
different groups had hypertension, which is one of the limitations of this study. Ivanovic-
Krstic et al. reported that in elderly persons with isolated systolic hypertension the aortic 
distensibility was significantly lower in comparison to normotensive subjects of the same age. 
They also found inverse correlation between the aortic distensibility and the mean systolic 
blood pressure (85). According to their findings, patients with non-significant CAD is a good 
example for the influence of hypertension on CFR as well as indices of aortic distensibility. 
However, where significant CAD was accompanied with hypertension, CFR and E(p) showed 
significant difference. E(s) in patients with LAD disease/MVD was also higher, but these 
values because of the high standard deviation and relatively low patient number showed no 
mathematical significance. These data underlines the fact, that vascular atherosclerosis has a 
higher influence on CFR and indices of aortic distensibility than hypertension. Previous 
studies also found that nifedipine administration increases the aortic distensibility in both 
normal subjects and patients with CAD (84). 
5.2.3 Coronary flow velocity reserve and indices of aortic distensibility in patients with 
different grades of aortic atherosclerosis 
Transoesophageal Doppler echocardiography can be used for the parallel evaluation of the 
grade of AA, the indices of aortic distensibility and the CFR. The CFR was reduced in 
patients with even minimal grade of AA in case of aortic intimal thickening relative to cases 
without relevant aortic atherosclerosis. Interestingly no further decrease was observed in 
patients with frank higher grades of AA (in the presence of different grades of aortic plaque). 
The indices of aortic distensibility increased continuously in parallel with the aortic grade, 
and significant differences were found between patients with grade 2-3 or with grade 0 or 1 
AA. 
Previous studies showed a strong correlation between aortic plaque and CAD. In the present 
study, an appreciable relationship has been found between CFR as a functional marker of the 
LAD stenosis as well as the presence of AA. This association has even been observed in the 
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occurance of intimal thickening as the minimal grade of AA. Increased aortic stiffness was 
incident to echocardiographically evaluated higher grade of AA. 
Comparison with previous studies: Thoracic aortic atherosclerosis determined by TEE in 
autopsy studies is associated with increasing age and the evidence of significant CAD was 
found earlier as in the present study (77,90-93). Aortic plaque is useful in the noninvasive 
prediction of the presence and severity of CAD as earlier discussed (70-77). Other authors 
found also good correlations between the atherosclerosis of periferial vessels and aorta as well 
as CAD (78). 
5.2.4. Coronary flow velocity reserve and indices of aortic distensibility in aortic stenosis 
patients with a negative coronary angiogram 
We have demonstrated a reduced CFR, characterizing the diminished reserve capacity of the 
LAD, and altered aortic distensibility (increased E(p) and E(s), as functional markers of the 
descending aorta) in AOS patients with normal epicardial coronary arteries and in cases with 
significant stenosis of the LAD as compared to patients without valvular heart disease or 
significant CAD. 
Previous studies demonstrated an impaired CFR in the presence of left ventricular 
hypertrophy as in aortic stenosis discussed earlier. The measurement of aortic wall thickness 
and stiffness is highly attractive measures of the structural and functional alterations caused 
by atherosclerosis, hypertension and other degenerative process (94). An increased aortic 
distensibility indices as functional markers of the descending aorta was found in AOS patients 
without epicardial CAD. As revealed by previous studies, the CFR is decreased in AOS, and 
increases during the long-term follow-up of AVR in parallel with the regression of left 
ventricular hypertrophy. Nevertheless, the CFR does not reached the level in patients without 
valvular heart disease or significant epicardial CAD, suggesting that other factors may also 
play a role in the pathogenesis of the impairment of the CFR in AOS. The present study has 
demonstrated a decreased aortic distensiblity and an appreciable stiffness of the descending 
aorta in AOS patients with normal epicardial coronary arteries. This result can be explained as 
an early manifestation of the atherosclerotic process, decreased perfusion of the aorta etc., and 
it requires further investigation. 
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6. Conclusions (new observations) 
1. There is a considerable benefit of prosthetic aortic valve replacement as concerns the 
coronary flow velocity reserve in patients with a normal coronary angiogram after a long-
time follow-up in parallel with the regression of left ventricular hypertrophy. 
2. Our results confirm that the grade of aortic atherosclerosis can be utilized to differentiate 
patients with aortic stenosis with severe LAD disease from AOS patients with a negative 
coronary angiogram. The CFR is unsuitable for the prediction and differentiation of these 
patient populations, cannot be regarded as a substitute for coronary angiography and from 
a practical point of view is useless. If grade 2-3 AA is found, the coronary angiography is 
advisable. 
3. There is a considerable stiffness of descending aorta in patients with AOS but with normal 
epicardial coronary arteries. The indices of aortic distensibility are similarly increased as 
to cases with significant LAD stenosis. 
4. The grade of AA furnishes additional help in the prediction of patients with severe 
coronary artery disease. The grade of AA can differentiate patients with multivessel 
disease (MVD) from those with significant LAD stenosis. CFR has no any predictive 
power in this evaluation. 
5. There is a decreased aortic distensibility (increased E(p) and E(s)) and also decreased CFR 
in patients with significant LAD stenosis and MVD as compared to patients with negative 
coronary angiogram. In patients with non-significant coronary artery stenosis, the CFR, 
mean CFR and stiffness moduli lie between those for negative cases and those for patients 
with LAD disease/MVD. Not only the CFRs, but also E(p) and E(s) displayed no further 
changes in cases with MVD as compared with LAD disease. 
6. The CFR is decreased in patients with aortic intimal thickening, but no further decrease 
was observed in the event of aortic plaque. The indices of aortic distensibility increased 
continuously in parallel with grade of AA. 
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